XML 58 R44.htm IDEA: XBRL DOCUMENT v3.19.2
Collaborative Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
May 06, 2016
Dec. 29, 2015
Dec. 24, 2018
Sep. 30, 2017
Sep. 25, 2017
Jul. 24, 2017
May 26, 2017
Feb. 28, 2017
Aug. 31, 2016
Jul. 27, 2016
Mar. 31, 2016
Dec. 31, 2015
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Collaborative Agreements (Textual)                                
Common stock newly issued, value                         $ 694,219 $ 80,000 $ 80,000 $ 5,850,000
Outstanding balance                             2,550,000
Collaborative Arrangement [Member]                                
Collaborative Agreements (Textual)                                
Description of payment settlement   Upfront payment shall upon the signing of this BioLite Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week. Upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week. At the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months. Upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week. At the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months. Upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.                            
Amount received from BriVision   $ 100,000,000       $ 3,000,000                    
Upfront payments   $ 3,500,000                            
Percentage of payments under co-development agreement   3.50%       50.00%                    
Milestone payments to BioLite in cash $ 2,600,000                              
Common stock newly issued, value $ 900,000         $ 3,000,000                    
Common stock newly issued, shares 562,500                              
Share price $ 1.60             $ 2.0                
Licensing rights         $ 3,000,000                      
Accounts payable                         $ 15,000,000   $ 15,000,000  
Research and development expense         $ 3,000,000                      
Agreement, terms   This BioLite Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term.                            
Co-Dev Agreement [Member]                                
Collaborative Agreements (Textual)                                
Amount received from BriVision       $ 3,000,000     $ 3,000,000                 450,000
Percentage of payments under co-development agreement             50.00%               15.00%  
Licensing rights                             $ 10,000,000  
Accounts payable                             $ 15,000,000  
Company cash payments       $ 3,000,000     $ 3,000,000                  
Co-Dev agreement, description     The Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene's Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.                          
BHK Co-Development Agreement [Member]                                
Collaborative Agreements (Textual)                                
Description of payment settlement                   Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment At the completion of first phase II clinical trial: $1 million, or 10% of total payment At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment            
Upfront payments                   $ 1,000,000   $ 1,000,000        
Percentage of payments under co-development agreement                   10.00%   10.00%        
Milestone payments to BioLite in cash                 $ 31,649,000 $ 10,000,000            
Common stock newly issued, value                 $ 1,000,000     $ 10,000,000        
Milestone payments royalty percentage                 12.00%              
Collaborative Agreements, description                       The Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK. In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of March 31, 2019 and 2018, the Company has not earned the royalty under the BHK Collaborative Agreements.      
Collaborative Arrangement One [Member]                                
Collaborative Agreements (Textual)                                
Percentage of payments under co-development agreement                     6.50%          
Milestone payments to BioLite in cash               $ 650,000                
Common stock newly issued, value               $ 5,850,000                
Common stock newly issued, shares               2,925,000                
Share price               $ 2.0                
Accounts payable                     $ 6,500,000          
Research and development expense                               $ 3,000,000